A. Şahin, M. Gül, Ö. Akyol, E. Simsek, F. Çelebi, Akar Karakoç
{"title":"Investigation of Serum NO, ADMA and Apelin Levels in Thyroid Dysfunction","authors":"A. Şahin, M. Gül, Ö. Akyol, E. Simsek, F. Çelebi, Akar Karakoç","doi":"10.7176/jmpb/67-03","DOIUrl":null,"url":null,"abstract":"Thyroid gland diseases are among the most common endocrine diseases and still continue to be an important health problem especially in developing countries. It was aimed to investigate serum NO, ADMA and Apelin levels in patients with thyroid dysfunction. This study was conducted with 150 thyroid patients and 50 healthy subjects. Study subjects were divided into three groups; control (n=50), hyperthyroid ( n=75) and hypothyroid (n=75). Serum TSH, FT3, FT4 levels were measured by chemiluminescence method NO level were measured by spectrophotometric method, ADMA and apelin levels were measured by ELISA. Serum NO levels were higher in hypothyroid group than in hyperthyroid group, and the difference was statistically significant. Serum ADMA levels of the hyperthyroid group were significantly higher than the other two groups and the difference was statistically significant. The levels of serum apelin were statistically significantly higher in the hyperthyroid group than the other two groups. In patients with hyperthyroidism, ADMA and Apelin levels were higher, while NO level was lower. However, NO level was higher in patients with hypothyroidims than the other two groups. Apelin, which has been emphasized as a preventive and therapeutic agent particularly for the cardiovascular system, might have increased in hyperthyroid patients, regardless of NO, to protect cardiovascular system from possible adverse effects of ADMA. Keywords: Asymmetric dimethylarginine, apelin, nitric oxide, thyroid dysfunction DOI: 10.7176/JMPB/67-03 Publication date: August 31 st 2020","PeriodicalId":16339,"journal":{"name":"Journal of Medicine, Physiology and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicine, Physiology and Biophysics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7176/jmpb/67-03","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Thyroid gland diseases are among the most common endocrine diseases and still continue to be an important health problem especially in developing countries. It was aimed to investigate serum NO, ADMA and Apelin levels in patients with thyroid dysfunction. This study was conducted with 150 thyroid patients and 50 healthy subjects. Study subjects were divided into three groups; control (n=50), hyperthyroid ( n=75) and hypothyroid (n=75). Serum TSH, FT3, FT4 levels were measured by chemiluminescence method NO level were measured by spectrophotometric method, ADMA and apelin levels were measured by ELISA. Serum NO levels were higher in hypothyroid group than in hyperthyroid group, and the difference was statistically significant. Serum ADMA levels of the hyperthyroid group were significantly higher than the other two groups and the difference was statistically significant. The levels of serum apelin were statistically significantly higher in the hyperthyroid group than the other two groups. In patients with hyperthyroidism, ADMA and Apelin levels were higher, while NO level was lower. However, NO level was higher in patients with hypothyroidims than the other two groups. Apelin, which has been emphasized as a preventive and therapeutic agent particularly for the cardiovascular system, might have increased in hyperthyroid patients, regardless of NO, to protect cardiovascular system from possible adverse effects of ADMA. Keywords: Asymmetric dimethylarginine, apelin, nitric oxide, thyroid dysfunction DOI: 10.7176/JMPB/67-03 Publication date: August 31 st 2020